PressReleases

Press Releases

Kineta Press Releases
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of
Kineta to Receive $5 Million Milestone Payment from Merck
Kineta to Receive $5 Million Milestone Payment from Merck Discovery stage milestone triggered by validating an undisclosed target for amyotrophic
Kineta Expands Board of Directors with Biotech Industry Leaders Kim Drapkin and Scott Dylla
SEATTLE, June 28, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel
Kineta Set to Join Russell Microcap® Index
SEATTLE, May 24, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel
Kineta to Present at Jefferies Healthcare Conference
SEATTLE, May 23, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel
Dosed First Patient in Phase 1/2 Clinical Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Initial KVA12123 Clinical Data Readout
Kineta, Inc. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
SEATTLE, April 24, 2023 — Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules SEATTLE, April 20, 2023 — Kineta,
Kineta Unveils New VISTA Biomarker Data and KVA12123 Phase 1/2 Clinical Trial Update at AACR Annual Meeting 2023
SEATTLE, April 17, 2023 — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel
Disclaimer: The Press Releases on this page are provided for historical purposes only. The information contained in each [press release/news article/event] is accurate only as of the date each was originally issued. Kineta disavows any obligation to update the information after the date of their issuance.